RecruitingPhase 2NCT05905887

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib

Sponsor

Asan Medical Center

Enrollment

48 participants

Start Date

Sep 6, 2023

Study Type

INTERVENTIONAL

Conditions

Gastrointestinal Stromal Tumors

Summary

The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Rivoceranib Mesylate, Paclitaxel for people with gastrointestinal stromal tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRivoceranib Mesylate, Paclitaxel

Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days). Rivoceranib 400 mg orally once a day.